<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02195167</url>
  </required_header>
  <id_info>
    <org_study_id>SEP360-105</org_study_id>
    <nct_id>NCT02195167</nct_id>
  </id_info>
  <brief_title>Dasotraline SEP360-105 Pediatric PK/PD Study</brief_title>
  <official_title>A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age With Attention Deficit Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharma America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Pharma America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric PK study of SEP-225289 (Dasotraline)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To characterize the pharmacokinetics (PK) and assess safety and tolerability of a range of&#xD;
      single oral doses of SEP-225289 in subjects 6 to 17 years old with ADHD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax), tmax, t1/2, area under the concentration from time zero to infinite time (AUC0-inf), and AUC0-last.</measure>
    <time_frame>0-51 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs, SAEs, and discontinuation due to AE</measure>
    <time_frame>0-51 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions-Severity of Illness (CGI-S) score and Columbia Suicide Severity Rating Scale (C-SSRS) evaluation.</measure>
    <time_frame>0-51 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values-changes from baseline in clinical laboratory tests, vital signs, orthostatic changes, and 12-lead electrocardiograms (ECGs).</measure>
    <time_frame>0-51 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F), apparent volume of distribution (Vz/F), and terminal elimination rate constant (λz).</measure>
    <time_frame>0-51 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximal reduction of plasma DHPG, percent maximal reduction of plasma DHPG concentration relative to baseline, minimal observed plasma DHPG concentration postdose, and time to minimal observed plasma DHPG concentration postdose.</measure>
    <time_frame>0-51 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Pediatric Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Dasotraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg.&quot; The language should precede the text that is currently there</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily</intervention_name>
    <description>Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg.&quot; The language should precede the text that is currently there</description>
    <arm_group_label>Dasotraline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subject, male or female, must be between 6 and 17 years of age, inclusive, at the time of&#xD;
        consent. Note: Subjects who are 17 years of age at time of consent must not have a birthday&#xD;
        within the following 4 weeks in order to be eligible for the study.&#xD;
&#xD;
          -  Subject meets Diagnostic and Statistical Manual of Mental Disorders Fourth Edition;&#xD;
             Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD (inattentive,&#xD;
             hyperactive, or combined subtype) established by a comprehensive psychiatric&#xD;
             evaluation that reviews DSM-IV-TR criteria prior to Screening. Diagnosis is confirmed&#xD;
             at Screening using Mini International Neuropsychiatric Interview for Children and&#xD;
             Adolescents (MINI-KID).&#xD;
&#xD;
          -  Subject's parents/legal guardians must give written informed consent, including&#xD;
             privacy authorization, prior to study participation. The subject will complete an&#xD;
             informed assent prior to study participation. Note: Informed consent will be obtained&#xD;
             from both parents unless one parent is deceased, unknown, incompetent, or when one&#xD;
             parent has legal responsibility for the care and custody of the child.&#xD;
&#xD;
          -  Subject and the subject's parents/legal guardians must be judged by the investigator&#xD;
             to be willing and able to comply with the study procedures and visit schedules,&#xD;
             including venipuncture, overnight stay (recommended for parent/legal guardian to&#xD;
             remain overnight with the subject), and follow-up visits.&#xD;
&#xD;
          -  Subject, if female, must not be pregnant or breastfeeding, and if ≥ 8 years of age&#xD;
             must have a negative serum pregnancy test at screening.&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects with female partners of&#xD;
             childbearing potential must agree to use an effective and medically acceptable form of&#xD;
             birth control throughout the study period.&#xD;
&#xD;
          -  Subject must be in general good health (defined as the absence of any clinically&#xD;
             relevant abnormalities as determined by the investigator) based on screening physical&#xD;
             and neurological examinations, medical history, and clinical laboratory values&#xD;
             (hematology, chemistry, and urinalysis). Note: If any of the hematology, chemistry, or&#xD;
             urinalysis results are not within the laboratory's reference range, then the subject&#xD;
             can be included only if the investigator determines the deviations to be not&#xD;
             clinically relevant.&#xD;
&#xD;
          -  Subject is within 3rd to 97th percentile for gender specific body mass index&#xD;
             (BMI)-for-age from the World Health Organization (WHO) growth charts (Appendix VI) and&#xD;
             weighs at least 25 kg.&#xD;
&#xD;
          -  Subject must report a history of being able to swallow capsules.&#xD;
&#xD;
          -  Subject and subject's parents/legal guardians must be able to fully comprehend the&#xD;
             informed consent/assent form, understand all study procedures, and be able to&#xD;
             communicate satisfactorily with the investigator and study coordinator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subject or parents/legal guardians have daily commitments during the study that would&#xD;
        interfere with attending study visits.&#xD;
&#xD;
          -  Subject has any clinically significant unstable medical abnormality, chronic disease,&#xD;
             or a history of a clinically significant abnormality of the&#xD;
             cardiovascular,gastrointestinal, respiratory, hepatic, or renal systems, or a disorder&#xD;
             or history of a condition (eg, malabsorption, gastrointestinal surgery) that may&#xD;
             interfere with drug absorption, distribution, metabolism, or excretion.&#xD;
&#xD;
          -  Subject has a history or presence of abnormal ECGs, which in the investigator's&#xD;
             opinion is clinically significant. Screening ECGs will be centrally over-read, and&#xD;
             eligibility will be determined based on the over-read report.&#xD;
&#xD;
          -  Subject has a documented history of Bipolar I or II Disorder, major depression,&#xD;
             conduct disorder, oppositional defiant disorder, generalized anxiety disorder (other&#xD;
             than obsessive-compulsive disorder) or any history of psychosis, that has been the&#xD;
             primary focus of treatment at any time during the 12 months prior to screening.&#xD;
&#xD;
          -  Subject has organic brain disease, for example, traumatic brain injury residua, or a&#xD;
             history of febrile seizures. Subjects taking anticonvulsants for seizure control&#xD;
             currently or within the past 2 years are not eligible for study participation.&#xD;
&#xD;
          -  Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; item 4 (active suicidal ideation with&#xD;
             some intent to act, without specific plan) or item 5 (active suicidal ideation with&#xD;
             specific plan and intent) on the C-SSRS Children's Lifetime/Recent assessment at&#xD;
             screening. Subjects who have significant findings for suicidal ideation upon&#xD;
             completion of the C-SSRS must be referred to the investigator for follow-up&#xD;
             evaluation.&#xD;
&#xD;
          -  Subject has any history of attempted suicide.&#xD;
&#xD;
          -  Subject does not tolerate venipuncture or has poor venous access that would cause&#xD;
             difficulty for collecting blood samples.&#xD;
&#xD;
          -  Subject has a history of severe allergies to more than 1 class of medications or&#xD;
             multiple adverse drug reactions.&#xD;
&#xD;
          -  Subject has history of exposure to stimulants with intolerable side effects.&#xD;
&#xD;
          -  Subject has taken any antipsychotic medication within 8 weeks of Visit 1 (Screening).&#xD;
&#xD;
          -  Subject is taking any psychotropic medication, including health-food supplements with&#xD;
             purported central nervous system activity (eg, St. John's Wort, melatonin), must have&#xD;
             a washout equal to a minimum of 5 half lives of that medication prior to Visit 2. If&#xD;
             the half life of a medication is unknown, for example, herbal products, then the&#xD;
             subject should have a 28 day medication washout.&#xD;
&#xD;
          -  Subject is currently taking an antidepressant medication (eg, bupropion, selective&#xD;
             serotonin reuptake inhibitor [SSRI]/ serotonin norepinephrine reuptake inhibitor&#xD;
             [SNRI], monoamine oxidase [MAO] blocker, tricyclic, etc).&#xD;
&#xD;
          -  Subject or subject's family anticipates a move outside the geographic range of the&#xD;
             investigative site during the study period, or plans extended travel inconsistent with&#xD;
             the recommended visit interval during study duration.&#xD;
&#xD;
          -  Subject has a history of, or current malignancy except for non melanoma skin cancer.&#xD;
&#xD;
          -  Subject has a positive screening test for Hepatitis B surface antigen, Hepatitis C&#xD;
             antibody, or human immunodeficiency virus (HIV)-1 or HIV-2.&#xD;
&#xD;
          -  Subject has participated in any investigational study within 30 days prior to&#xD;
             screening or is currently participating in another clinical trial.&#xD;
&#xD;
          -  Subject has a history of substance abuse or drug dependence (excluding nicotine and&#xD;
             caffeine) within the 12 months prior to screening, as defined by the DSM IV TR&#xD;
             criteria or has a positive urine drug screen (UDS), cotinine test, or breath alcohol&#xD;
             test at Visit 1.&#xD;
&#xD;
          -  Subject is taking any disallowed medications for chronic treatment.&#xD;
&#xD;
          -  Subject has experienced significant blood loss within 60 days or has donated plasma&#xD;
             within 72 hours prior to Visit 1 or intends to donate blood or undergo elective&#xD;
             surgery within 30 days following Visit 2.&#xD;
&#xD;
          -  Subject has a history of allergic reaction or has a known or suspected sensitivity to&#xD;
             any substance that is contained in the study drug formulation.&#xD;
&#xD;
          -  Subject is a relative of an investigational site staff member.&#xD;
&#xD;
          -  Subject is, in the opinion of the investigator, unsuitable in any other way to&#xD;
             participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dasotraline Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Pharma America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Springs Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Associates, Inc</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc. (CTT)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02195167
org study id: SEP360-105
nct id: NCT02195167
lead sponsor: 
has dmc: No
Pediatric PK study of SEP-225289 (Dasotraline)
To characterize the pharmacokinetics (PK) and assess safety and tolerability of a range of
      single oral doses of SEP-225289 in subjects 6 to 17 years old with ADHD
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Maximum concentration (Cmax), tmax, t1/2, area under the concentration from time zero to infinite time (AUC0-inf), and AUC0-last.
time frame: 0-51 Days
measure: Incidence of AEs, SAEs, and discontinuation due to AE
time frame: 0-51 Days
measure: Clinical Global Impressions-Severity of Illness (CGI-S) score and Columbia Suicide Severity Rating Scale (C-SSRS) evaluation.
time frame: 0-51 Days
measure: Absolute values-changes from baseline in clinical laboratory tests, vital signs, orthostatic changes, and 12-lead electrocardiograms (ECGs).
time frame: 0-51 Days
measure: Apparent clearance (CL/F), apparent volume of distribution (Vz/F), and terminal elimination rate constant (λz).
time frame: 0-51 Days
measure: Time to maximal reduction of plasma DHPG, percent maximal reduction of plasma DHPG concentration relative to baseline, minimal observed plasma DHPG concentration postdose, and time to minimal observed plasma DHPG concentration postdose.
time frame: 0-51 Days
arm group label: Dasotraline
arm group type: Experimental
description: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg." The language should precede the text that is currently there
intervention type: Drug
intervention name: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
description: Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg." The language should precede the text that is currently there
arm group label: Dasotraline
criteria: 
gender: All
minimum age: 6 Years
maximum age: 17 Years
healthy volunteers: No
last name: Dasotraline Medical Director, MD
role: Study Director
affiliation: Sumitomo Pharma America, Inc.
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Hyperkinesis
mesh term: Attention Deficit Disorder with Hyperactivity